General
Preferred name
DINACICLIB
Synonyms
MK-7965, SCH-727965 ()
SCH727965 ()
SCH 727965 ()
PS-095760 ()
Dinaciclib (SCH 727965) ()
MK-7965 ()
SCH-727965 ()
Dinaciclib (SCH727965) ()
P&D ID
PD003528
CAS
779353-01-4
Tags
available
obsolete probe
drug candidate
Drug indication
Acute lymphoblastic leukaemia
Drug Status
investigational
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Dinaciclib is a potent cyclin-dependent kinase (CDK) inhibitor, inhibiting the CDK4 and 6 isoforms . Dinaciclib has also been reported to interact with the acetyl-lysine recognition domain of the bromodomain testis-specific protein BRDT . BRDT is a member of the BET family of bromodomain-containing proteins which are considered to be atypical kinases.
SARS-CoV-2: SARS-CoV-2 may regulate the host cell cycle to enhance viral replication, and in vitro phosphoproteomics analysis suggests that viral hijacking of the CDK signalling pathway may, at least in part, mediate this mechanism . Pharmacological inhibition of the CDK pathway with dinaciclib has anti-SARS-CoV-2 activity in two model cells lines, A549-ACE2 cells (IC50 32 nM) and Vero E6 cells (IC50 127 nM). (GtoPdb)
SARS-CoV-2: SARS-CoV-2 may regulate the host cell cycle to enhance viral replication, and in vitro phosphoproteomics analysis suggests that viral hijacking of the CDK signalling pathway may, at least in part, mediate this mechanism . Pharmacological inhibition of the CDK pathway with dinaciclib has anti-SARS-CoV-2 activity in two model cells lines, A549-ACE2 cells (IC50 32 nM) and Vero E6 cells (IC50 127 nM). (GtoPdb)
DESCRIPTION
inhibitor of cyclin-dependent kinases
(Informer Set)
DESCRIPTION
Potent steroid sulfatase inhibitor; also inhibits carbonic anhydrase II
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
40
Organisms
2
Compound Sets
19
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
CDK inhibitor database (CDKiDB)
ChEMBL Drugs
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DrugMAP
Guide to Pharmacology
Informer Set
LINCS compound set
MedChem Express Bioactive Compound Library
Obsolete Compounds
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Molecular Weight
396.23
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
3
cLogP
2.28
TPSA
92.63
Fraction CSP3
0.48
Chiral centers
1.0
Largest ring
6.0
QED
0.47
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
CDK1
CDK2
CDK5
CDK9
CDK1, CDK2, CDK5, CDK9
CDK4
CDK6
BRDT
Caspase,CDK
Compound status
clinical
Targets
CDK2,CDK5,CDK1,CDK9
Pathway
Cell Cycle/Checkpoint
Apoptosis
Cell Cycle/DNA Damage
Primary Target
CDK1 Subfamily
MOA
CDK
Inhibitor
CDK inhibitor
Source data
